A Phase 1, Multi-center, Open-label Study of IMGN632 Administered Intravenously in Patients with Relapsed/Refractory CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
The goal of this clinical research study is to find the highest tolerable dose of IMGN632 that can be given to patients with acute myeloid leukemia (AML) or other hematologic malignancy (blood disease) that has not responded to treatment or has come back after treatment. Researchers also want to learn what effects, good and/or bad, the study drug may have on you and the disease.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: IMGN632
Treatment Location: Both at MDACC & and Other Sites
Sponsor: ImmunoGen, Inc.
IRB Review and Approval Date: 12/27/2017
Recruitment Status: Open
Projected Accrual: 232
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: